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Introduction
African sleeping sickness threatens >60 million people in sub-
Saharan Africa, resulting in >70,000 deaths per year, and addi-
tional impact is felt through its effects on livestock. The disease 
is always fatal if untreated, and existing drugs are unacceptably 
toxic and often require hospitalization (Barrett et al., 2003). 
With outdated existing drugs, new targets for drug development 
are urgently needed. This search is being aided by a better un-
derstanding of the biology of the causative agent, Trypanosoma 
brucei spp.
The life cycle of T. brucei is divided between a mam-
malian host and the tsetse fl y (Matthews, 2005). In mammals, 
the parasite population consists of proliferative slender cells 
and nonproliferating stumpy forms, which are arrested in 
G1/G0 (Matthews et al., 2004). The transition between these 
forms occurs in response to a parasite-derived signal in the 
bloodstream (Vassella et al., 1997), resulting in an accumula-
tion of stumpy forms. This optimizes parasite  transmissibility 
 because stumpy forms are preadapted for uptake into the  tsetse 
fl y (Engstler and Boshart, 2004). In particular, they have up-
regulated certain metabolic activities in preparation for life 
in the fl y and are more resistant to proteolytic attack and pH 
fl uctuations (Sbicego et al., 1999; Nolan et al., 2000). In the 
tsetse, stumpy forms differentiate to procyclic forms, a trans-
ition that can be effi ciently reproduced in culture by cis aconi-
tate and a reduction of temperature (Ziegelbauer and Overath, 
1990). Once stimulated to differentiate, stumpy forms embark 
on a precisely programmed developmental pathway involving 
changes in cell morphology, metabolic activity, surface antigen 
expression, and gene expression. Importantly, the generation 
of stumpy forms in the bloodstream represents an  irreversible 
commitment to differentiate; stumpy forms not taken up in a fl y 
blood meal ultimately degenerate in the bloodstream (Turner 
et al., 1995).
In higher eukaryotes, tyrosine phosphorylation is a well-
characterized mechanism for regulating cell growth and differ-
entiation, as well as many other aspects of cell life (Neel and 
Tonks, 1997; Tonks, 2003). However, less is known about tyro-
sine phosphorylation events in lower eukaryotes and prokary-
otes. For example, in bacteria, protein tyrosine phosphorylation 
is a rare occurrence and yet tyrosine phosphatases are essential 
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for infection and survival of pathogenic species like Salmonella, 
Yersinia, or Mycobacterium (Black et al., 2000; Lin et al., 2003; 
Singh et al., 2003). Kinetoplastid parasites such as Trypano-
soma spp. and Leishmania spp. occupy an interesting evolution-
ary niche, being unicellular organisms and among the most 
diverged representatives of the eukaryotic world. Although in-
tracellular signaling events have not yet been described in detail 
for these organisms, it is likely that tyrosine phosphorylation 
will also play a role in cellular processes as in higher eukary-
otes. Supporting this, there is evidence that several proteins are 
phosphorylated on tyrosine residues in kinetoplastids (Parsons 
et al., 1991; Cool and Blum, 1993) presumably through the ac-
tivity of dual-specifi city protein kinases, as kinetoplastid ge-
nomes do not encode any recognizable tyrosine-specifi c kinases 
(Parsons et al., 2005). Tyrosine phosphatase activity also shows 
marked differences among different life cycle stages in both 
T. brucei and T. cruzi (Bakalara et al., 1995a).
From the precedent in higher eukaryotes, it is likely that 
phosphotyrosine phosphatases will be also relevant in the con-
trol of cell growth and development in kinetoplastids. Support-
ing this idea, it was recently reported that the heterologous 
expression of the human PTP1B gene in Leishmania, together 
with the inhibition of tyrosine kinases, promoted partial differ-
entiation from promastigote to amastigote forms (Nascimento 
et al., 2003). Here, we demonstrate that the activity of a T. 
brucei protein tyrosine phosphatase, TbPTP1, exhibits a pivotal 
function in parasite differentiation. Biochemical characteriza-
tion of the enzyme demonstrates that it is a tyrosine-specifi c 
phosphatase whose enzymatic activity is regulated by pH and 
changes in its oxidation state. Importantly, when TbPTP1 activ-
ity is inhibited by RNAi or biochemically, differentiation to 
procyclic forms occurs spontaneously in the absence of any 
exogenous trigger. This response is restricted to a subset of 
bloodstream cells, which we propose are those already commit-
ted to differentiation. Supporting this, tyrosine phosphatase in-
hibition in a homogeneous population of stumpy forms triggers 
synchronous, effi cient, and complete differentiation to prolifer-
ative procyclic forms. These data reveal that a tyrosine phos-
phatase activity is a key molecular regulator of the initiation of 
trypanosome differentiation, providing a potential pharmaco-
logical target to restrict parasite transmissibility and virulence.
Results
Identiﬁ cation and expression proﬁ le 
of TbPTP1
To identify molecules implicated in the differentiation compe-
tence of bloodstream stumpy forms, we searched the T. brucei 
genome database for molecules that defi ne G1/G0 arrest in 
other organisms. This revealed a 595-bp fragment with limited 
sequence similarity to the protein tyrosine phosphatase PTPROt 
(Aguiar et al., 1999). PTPROt was fi rst identifi ed in mammalian 
lymphoid organs and is up-regulated in quiescent B cells. The 
intact T. brucei gene was then isolated by PCR from cDNA, 
and the complete gene sequence was determined. This was 
subsequently verifi ed upon completion of the T. brucei genome 
project. This gene, which we have named TbPTP1 (T. brucei 
phosphotyrosine phosphatase 1), is positioned on chromosome 
10 (Tb10.70.0070).
Previous evidence that protein phosphatase activities 
were differentially regulated during the trypanosome life cycle 
(Bakalara et al., 1995b) prompted us to examine the developmen-
tal mRNA expression profi le of TbPTP1 by Northern blotting. 
Total RNA was prepared from monomorphic bloodstream slender 
forms, bloodstream stumpy forms, and in vitro–cultured procy-
clic forms. This revealed that the TbPTP1 mRNA was expressed 
in all stages examined, although up-regulated in stumpy forms 
(1.5–3-fold), which was somewhat variable between samples 
(Fig. 1 A). To relate mRNA expression to that of the protein, an 
anti-peptide antibody was raised against the sequence N-A M K Q-
K R F G M V Q R L E Q -C from the amino acid sequence at position 
265–279 in TbPTP1. When reacted against lysates derived from 
isogenic monomorphic slender and stumpy forms of T.b. rhode-
siense EATRO 2340 and procyclic forms of T. brucei Lister 427, 
approximately equal expression of TbPTP1 protein was detected. 
TbPTP1 expression was also analyzed during synchronous dif-
ferentiation of bloodstream stumpy forms to procyclic forms. 
This revealed no transient changes in the protein expression lev-
els of TbPTP1 during the events of differentiation (Fig. 1 B). 
Finally, analysis of the subcellular localization of TbPTP1 by 
differential detergent extraction revealed that TbPTP1 associated 
predominantly with the cytoskeletal fraction in bloodstream 
forms (Fig. 1 C). Although no association with any discrete 
structure (e.g., the fl agellum) could be detected (Fig. S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200605090/DC1), 
a cytoskeletal association for TbPTP1 matches the distribu-
tion of several tyrosine phosphatases characterized in other or-
ganisms (Howard et al., 1993; van Ham et al. 2005). This 
compartmentalization is believed to contribute to their 
substrate specifi city.
Figure 1. TbPTP1 is uniformly expressed during the trypanosome life 
 cycle and localizes with the cytoskeletal fraction. (A) Northern and Western 
analysis of TbPTP1 levels in slender (Sl), stumpy (St; both T.b. rhodesiense 
EATRO 2340) and procyclic (Pc; T.b. brucei s427) cells. Loading controls 
of ethidium bromide–stained total RNA (for the Northern blot) and α-tubulin 
(for the Western blot) are shown. (B) Protein expression of TbPTP1 during 
synchronous differentiation to procyclic forms. (C) Cellular distribution of 
TbPTP1 in stumpy forms. Cytosolic, membrane, nuclear, and cytoskeletal 
fractions are shown. TbPTP1 associates with the cytoskeletal fraction. Other 
cellular markers partition as expected (cPGK, cytosolic; BiP, membrane 
and cytosolic; and α-tubulin, cytoskeletal and cyotosolic; not depicted).
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The TbPTP1 is a member of a 
trypanosome-speciﬁ c PTP1 family
The 1.8-kb TbPTP1 mRNA contains an ORF of 921 nucleotides 
encoding a protein of 306 amino acids with a predicted molecu-
lar mass of 34 kD. A predicted PEST sequence region is located 
between residues 135 and 152 (Fig. 2, underlined). Analysis of 
the amino acid sequence of TbPTP1 revealed an N-terminal 
region (43 residues) with no apparent homology to any other 
protein and a C-terminal region (263 residues) that is homolo-
gous to the human protein tyrosine phosphatases PTP1B and 
PTPROt (24 and 23% identity over the catalytic domain of each 
molecule, respectively). An extensive search of different 
trypanosomatid databases, identifi ed orthologues of TbPTP1 in 
T. congolense (TcgPTP1, with 74.1% identity), T. vivax (TvPTP1, 
with 62.0% identity), and T. cruzi (TcPTP1, with 61.3% identity). 
The sequence alignment of these orthologues together with hu-
man PTP1B is shown in Fig. 2. When sequence similarity is 
considered, these values rise to 71–80% between TbPTP1 and 
trypanosomal PTP1s, compared with 38% to human PTP1B. 
In contrast, Leishmania major has a syntenic gene encoding a 
predicted tyrosine phophatase less closely related to TbPTP1 
(42% similarity; LmjF36.2180).
Previous sequence analysis of human PTPs have led to the 
identifi cation of 10 conserved motifs, some of which are impor-
tant in substrate binding and catalysis (Andersen et al., 2001). 
The trypanosomal PTP1 subfamily contains all the landmark 
motifs present in classical tyrosine-specifi c phosphatases (Fig. 2). 
These include the phospho-Tyr binding motif (Fig. 2, M1); the 
WPD loop (M8), which contains the catalytic aspartic acid (the 
general acid in catalysis); the catalytic P-loop or PTP signature 
motif (V/I)HCSAGXGR (T/S) (M9); and the Q-loop (M10), 
which is part of the active site in classic PTPs. Motifs 3–7 
(M3–M7) are also present in trypanosomal PTP1s with 
a high percentage of conservation, consistent with their role as 
structural motifs located in the core of the PTP catalytic domain. 
In total, 9 of the 10 well-conserved PTP motifs identifi ed in the 
mammalian enzymes are present in all the examined trypano-
some PTP1s, with only the less-conserved motif 2 missing. 
 Instead of motif 2, a trypanosome-specifi c motif, T1, replaces 
this structural motif.
Other distinct motifs were also identifi ed in the trypano-
somal PTP1s, generating a total of four trypanosome-specifi c 
motifs in the catalytic region (Fig. 2, T1–T4). These are as fol-
lows: T1 at position 55–63, “LANEXTIYP”; T2 at position 
165–167, “EVD”; T3 at position 239–244, “LIGAYA”; and T4 
at position 290–295, “RLGV (D/S) (I/V).” In addition, two 
other motifs have been identifi ed in the precatalytic (Pc) region: 
PcT1 “R (M/L)QREFXQLQ” at position 20–29 and PcT2 
“ENPRXI (D/N)FTTSL” at position 32–43. These precatalytic 
motifs are well conserved in all members of the T. brucei clade 
(T. brucei, T. congolense, and T. vivax) and less conserved in 
T. cruzi. A BLAST search failed to identify any of these motifs 
in other proteins, indicating that they are unique to the trypano-
somal PTP1 family. We hypothesize that these trypanosome-
specifi c motifs may be relevant to regulation of TbPTP1 or 
molecular recognition of other cellular targets.
The activity of TbPTP1 is regulated 
by reversible oxidation in vitro
Having identifi ed TbPTP1 as a putative tyrosine phosphatase, it 
was important to characterize its enzymatic activity profi le and 
substrate specifi city. For this, recombinant protein was pro-
duced for the wild-type protein and for two TbPTP1 mutants, 
one for the putative catalytic cysteine, Cys 229 (in the P-loop) 
and one for the catalytic Asp 199 (in the WPD loop). The cata-
lytic mutants of TbPTP1 were generated by mutating Cys 229 
to serine (C229S) and Asp 199 to alanine (D199A). The wild-
type enzyme and mutant enzymes were expressed as His6-
tagged fusions and purifi ed to >95% homogeneity. After 
removal of the His tag by enterokinase digestion, multiangle 
Figure 2. Alignment of TbPTP1 with ortho-
logue trypanosome PTP1s and the human 
PTP1B. The deduced amino acid sequences 
encoding PTP1 of T. brucei (Tb10.70.0070), 
T. congolense (congo1301f01.p1k), T. vivax 
(Tviv1180b04.p1k), T. cruzi (Tc00.10470535
10187.234), and the human PTP1B (P18031) 
were aligned using CLUSTAL X (Thompson 
et al., 1997). The classical PTP motifs are indi-
cated above the sequences in white boxes 
(M1–M10). The trypanosome-speciﬁ c motifs 
are boxed in gray. PcT1 and PcT2 are the 
precatalytic motifs, and the T1–T4 motifs are 
conserved in the catalytic region. The pre-
dicted PEST sequence is underlined. 
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light scattering analysis of the enzyme showed that TbPTP1 be-
haves as a monomeric protein in solution, with a determined 
mass of 35,140 D.
The phosphatase activities of the purifi ed recombinant 
wild-type, D199A, and C229S enzymes were assayed using var-
ious concentrations of p-nitrophenylphosphate (pNPP), a widely 
used substrate of tyrosine phosphatases. The pH profi le analysis 
of pNPP dephosphorylation demonstrated that the wild-type en-
zyme has the highest specifi c activity at pH 6.0 (Fig. 3 A), in 
agreement with the fact that PTPs in general have optimal enzy-
matic activities at low pH values. The mutant enzyme D199A 
showed low activity (5–8% of the wild type), and the C229S 
mutant enzyme was totally inactive under any assay condition 
and substrate concentration tested (unpublished data). This 
confi rms our predictions from the sequence analysis and demon-
strates that both residues, Cys 229 and Asp 199, are essential in 
the mechanism of catalysis of TbPTP1, matching their ortho-
logues in mammalian PTPs. Steady-state kinetic analysis of the 
wild-type enzyme yielded a Vmax value of 0.12 mM min−1 and a 
kcat/Km of 3.57 mM−1 × s−1 for the dephosphorylation of pNPP. 
Addition of 2 mM of DTT had a marked effect on the catalytic 
rate, increasing the Vmax by threefold and the kcat/Km by 14-fold 
(Fig. 3 B and Table S1, available at http://www.jcb.org/cgi/
content/full/jcb.200605090/DC1), consistent with previous 
 observations suggesting that the catalytic cysteine needs to be in 
a reduced state for effi cient nucleophilic attack of the substrate 
(Denu and Tanner, 1998). To investigate whether redox events 
(Denu and Tanner, 1998; Salmeen et al., 2003; van Montfort 
et al., 2003) could infl uence the enzymatic activity of TbPTP1, 
we performed a time course activity assay using increasing 
amounts of the oxidizing agent, hydrogen peroxide (H2O2). 
Fig. 3 C shows that after 10 min of incubation, the addition of 
0.25 mM H2O2 completely inactivated TbPTP1 and 0.025 and 
0.1 mM H2O2 reduced the enzyme activity by 37 and 58%, 
 respectively. Importantly, the enzymatic activity of the inactive 
TbPTP1 toward pNPP was completely restored after 5 min of 
 incubation with 10 mM DTT. These experiments indicate that 
TbPTP1 is sensitive to reversible redox regulation, consistent with 
several characterized mammalian PTPs (Denu and Tanner, 1998).
TbPTP1 is a tyrosine-speciﬁ c 
protein phosphatase
To test the specifi c activity of TbPTP1, a full kinetic character-
ization of the wild-type enzyme was undertaken using a range 
of phosphorylated substrates. These included tyrosine-, serine-, 
and threonine-phosphorylated peptides; phospho–amino acids; 
nucleotides; phospholipids; and inorganic phosphorylated com-
pounds (Fig. 4 A and Table S1). Most important, this analysis 
showed that TbPTP1 favored tyrosine-phosphorylated substrates 
in the dephosphorylation assays while showing 10–40-fold less 
activity against the Ser/Thr-phosphorylated substrates. In contrast, 
TbPTP1 exhibited little or no activity toward the phospholipids, 
nucleotides, or inorganic phosphocompounds tested, suggesting 
that the purifi ed enzyme does not exhibit either lipid phosphatase 
or phosphoesterase activity. Analysis of the saturation kinetics 
of TbPTP1 was also performed using the Tyr-phosphorylated 
EGF receptor peptide (pEGFR), the Insulin receptor peptide 
(pInsulin), phospho-Tyr (pTyr), and phospho-Ser (pSer). The 
results obtained showed that TbPTP1 dephosphorylates the 
pEGFR peptide with the highest Vmax, 1.5–2 times higher than 
for pInsulin peptide and pTyr, and six times higher than for 
pSer. As activity toward nucleotides, phospholipids, and inor-
ganic phospocompounds was considerably lower or nonmea-
surable, no further kinetic analysis was considered relevant for 
these compounds.
In a fi nal series of biochemical experiments, the inhibitor 
profi le of TbPTP1 was investigated. The phosphatase activity of 
TbPTP1 was assayed using pNPP or pEGFR peptide in the 
presence of different inhibitors. The PTP-specifi c inhibitor 
Figure 3. TbPTP1 activity is regulated by pH and redox. (A) Activity pro-
ﬁ le of TbPTP1 at different pH. (B) Effect of DTT on the speciﬁ c activity of 
 TbPTP1. Activity was determined using various concentrations of pNPP 
with the assay buffer adjusted to pH 6.0. The assays were performed with-
out DTT (open squares) or with 2 mM DTT (closed squares). (C) Reversible 
oxidation regulates TbPTP1 activity. TbPTP1 was inactivated with the ad-
dition of H2O2 and reactivated by the addition of DTT as reducing agent. 
TbPTP1 was treated with various concentrations of H2O2: control/0 mM 
(open circles), 0.025 mM (closed triangles), 0.1 mM (closed squares), and 
0.25 mM (closed circles). After the addition of H2O2, samples were tested 
for pNPP hydrolysis. After a 15-min incubation, 10 mM DTT was added to 
the samples to reactivate the oxidized-inactivated enzyme. The activity of 
the untreated enzyme is shown for comparison along the reduced/ oxidized 
sample. All data points represent the means of triplicate determinations. 
Error bars indicate SEM. pNP, p-nitrophenol. 
TRYPANOSOMA BRUCEI DIFFERENTIATION • SZÖO ˝ R ET AL. 297
sodium orthovanadate impaired the catalytic activity of TbPTP1 
in a concentration-dependent manner (Fig. 4 B). Dephosphory-
lation of both pNPP and of the pEGFR peptide was reduced by 
90% by 1 mM sodium orthovanadate, and the activity was com-
pletely abolished by 10 mM of this PTP inhibitor. In contrast, 
the Ser/Thr phosphatase inhibitor sodium fl uoride had no mea-
surable effect on the activity of TbPTP1 toward either pNPP or 
pEGFR, even at concentrations of 50 mM. Likewise, no effect 
was observed with the PP1- and PP2A-specifi c inhibitor oka-
daic acid or with the alkaline phosphatase inhibitor tetramisole. 
Combined, these experiments confi rmed our prediction, based 
on sequence analysis, that TbPTP1 exhibits all the biochemical 
characteristics typical of a tyrosine-specifi c phosphatase.
TbPTP1 ablation induces spontaneous 
differentiation to procyclic forms 
in a subset of bloodstream forms
To initiate a functional analysis in vivo, TbPTP1 was targeted in 
cultured bloodstream forms by RNAi. The TbPTP1 coding region 
was inserted into the vector pZJM (Wang et al., 2000) between 
two opposing T7 RNA polymerase promoters and transfected 
in to the “single marker” bloodstream line, which expresses T7 
RNA polymerase (Wirtz et al., 1999). This results in TbPTP1 
double-stranded RNA expression, thereby invoking RNAi. 
We successfully generated several viable cell lines, although 
in only one case was effective ablation of TbPTP1 mRNA 
and loss of protein observed, and this generated a subtle 
growth phenotype (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200605090/DC1). During phenotypic 
characterization of this cell line, we observed that a small 
proportion (2–12%) of cells spontaneously differentiated to 
procyclic forms despite maintenance of the cells in blood-
stream form culture conditions (HMI-9 culture medium 
at 37°C). This phenotype manifested itself as the presence 
of cells in the population that stained strongly with antibodies 
specifi c for both EP and GPEET (Fig. 5 A) procyclin (Roditi 
and Clayton, 1999). Signifi cantly, this did not represent loss of 
procyclin gene expression control alone (as can be observed 
at a frequency of up to 0.1% in wild-type bloodstream popu-
lations); analysis of the procyclin-stained cells indicated that 
they also exhibited characteristic procyclic-form morphology, 
with their mitochondrial genome (kinetoplast) being positioned 
away from the cell posterior (Matthews et al., 1995; Fig. 5 B). 
They also expressed the procyclic stage–specifi c cytoskeletal 
antigen CAP5.5 (Hertz-Fowler et al., 2001; unpublished data). 
Unfortunately, the differentiation phenotype was rapidly unsta-
ble and thus diffi cult to maintain in culture, with the proportion 
of differentiated cells decreasing in successive passages, even in 
the absence of induction.
The instability of the phenotype observed with TbPTP1 
RNAi prompted a search for alternative approaches to target the 
activity of this enzyme. Recently, a series of highly specifi c 
sulphonamido-benzabromarone allosteric inhibitors of PTP1B 
have been reported (Wiesmann et al., 2004), of which 3-(3,5-Di-
bromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-
(4-(thiazol-2-ylsulfamyl)-phenyl)-amide (BZ3) exhibits good 
Figure 4. TbPTP1 shows a tyrosine-speciﬁ c protein phosphatase activity 
and inhibitor proﬁ le. (A) Various phosphosubstrates (2 mM ﬁ nal concentra-
tion) were assayed using a malachite green detection system. The tyrosine-
phosphorylated EGFR (DADEpYLIPQQG) and insulin receptor 
(TRDIpYETDYYRK) were dephosphorylated with the highest rate followed 
by phosphoTyr amino acid. Other phosphosubstrates proved to be poor 
substrates for TbPTP1. (B) Effect of various inhibitors on the activity of 
TbPTP1. Concentrations and names of the inhibitors (OA, okadaic acid; 
Tetram, tetramisole) are indicated on the x axis. The fraction (%) of residual 
activities in the presence or in the absence of inhibitors is shown on the 
y axis. The ﬁ lled columns show activity measured using pNPP as substrate, 
and the empty columns show the phosphatase assays performed using 
pEGFR as substrate. All data points represent the mean values of triplicate 
determinations, and error bars (± SEM) are indicated. 
Figure 5. RNAi for TbPTP1 in bloodstream forms. RNAi of TbPTP 1 in 
T. brucei 427 single-marker bloodstream forms generates differentiated 
procyclic forms at 37°C in HMI-9. (A) A ﬁ eld with cells stained for EP or 
GPEET procyclin (arrows). (B) A cell where the kinetoplast is also posi-
tioned subterminally and there is EP procyclin staining. Bars, 15 μm.
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cell permeability. This compound prevents closure of the PTP1B 
WPD loop, thereby preventing dephosphorylation of substrates. 
To investigate whether this would provide a useful reagent for 
functional analysis of TbPTP1, we tested the inhibition profi le 
and specifi city of BZ3 against TbPTP1 and other PTPs. We 
found that 10 μM of BZ3 reduced the activity of TbPTP1 at least 
50%, consistent with its activity against human PTP1B (IC50 = 
8 μM; Wiesmann et al., 2004), whereas a dual-specifi city phos-
phatase and the human low molecular weight phosphatase 
HCPTPB, which lacks the WPD loop, showed no inhibition at 
this concentration (Fig. 6).
Having verifi ed the specifi city of BZ3 for TbPTP1, we 
exposed monomorphic bloodstream forms in culture to a titra-
tion of BZ3 ranging from 50 to 150 μM, which was in the same 
range as the concentration effective against mammalian PTP1B 
in CHO cells in culture (250 μM; Wiesmann et al., 2004). 
Strikingly, this also resulted in spontaneous differentiation of a 
subset of the parasites in response to the inhibitor, with 150 μM 
BZ3 stimulating procyclin expression in the bloodstream 
population at a frequency of 9.4% (Table I). Moreover, the 
phenotype of the cells was consistent with that observed in 
the RNAi line; i.e., the procyclin expressers in the population 
also exhibited kinetoplast repositioning, indicative of morpho-
logical differentiation (unpublished data). In contrast, exposure 
of monomorphic bloodstream forms to a non–cell-permeable 
PTP inhibitor, sodium orthovanadate (at 1 mM), did not result 
in detectable differentiation, nor did exposure to 1 mM NaF, a 
Ser/Thr phophatase inhibitor (Table I). Thus, TbPTP1 inhibition 
promotes spontaneous differentiation to procyclic forms in the 
absence of exogenous trigger in a subset of bloodstream forms 
in culture.
To verify that TbPTP1 was a target of BZ3 in vivo and that 
this was linked to the differentiation phenotype observed, trans-
genic bloodstream cells lines were generated which ectopically 
expressed wild type or a D199A mutant of TbPTP1, which binds 
but not release substrates (Tonks, 2003), acting as a dominant-
negative mutation (Fig. 7). When exposed to 150  μM BZ3, cells 
expressing the D199A mutant reproducibly exhibited signifi -
cantly enhanced differentiation when compared with the same 
cell line in the absence of tetracycline induction (18.1% in the 
induced population versus 11.6% in the uninduced population; 
Tukey post hoc comparison, P = 0.049). In contrast, no en-
hanced differentiation was observed in cells that ectopically 
expressed the wild-type TbPTP1 (9% in the induced population 
versus 10.3% in the uninduced population; P = 0.86). This dem-
onstrates that expression of the D199A mutant of TbPTP1 
increases differentiation in response to BZ3. This provides fur-
ther evidence that TbPTP1 is a target of BZ3 in vivo and that this 
is linked to the observed differentiation phenotype.
BZ3 stimulates synchronous 
differentiation of stumpy forms
We wished to investigate why only a subset of monomorphic 
bloodstream trypanosomes underwent spontaneous differentiation 
Figure 6. BZ3 (0, 2, or 10 𝛍M) inhibition of recombinant TbPTP1, human 
low molecular weight phosphatase (HCPTPB), and a mammalian dual-
speciﬁ city phosphatase. In each case, pNPP was used as substrate. Error 
bars indicate SEM.
Figure 7. BZ3 induced differentiation in bloodstream forms expressing 
wild-type TbPTP1-Ty or the D199A TbPTP1 mutant. For each, transgene ex-
pression was induced (+Tet) or not (−Tet) for 3 d, with cells then being ex-
posed to 150 μM BZ3. Expression of EP procyclin was assayed in 500 
cells after 24 h. Induction of each ectopically expressed protein was veri-
ﬁ ed by Western blotting using an antibody (BB2) directed against the Ty-1 
epitope tag incorporated into each protein. The results of three indepen-
dent experiments are shown, with error bars indicating the SEM. There was 
no difference in growth kinetics between each line before BZ3 addition 
(not depicted).
Table I. Percentage of EP procyclin–positive cells in monomorphic 
cultures treated with phosphatase inhibitors
Treatment EP procyclin–positive cells
%
Untreated monomorphic cells 0.3
+ DMSO 0
+ 50 μM BZ3 1.6
+ 100 μM BZ3 5.2
+ 150 μM BZ3 9.4
+ 1 mM NaOVanadate 0.6
+ 1 mM NaF 0.2
Cell samples were processed after 18 h under each condition.
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to procyclic forms when TbPTP1 was inhibited. Monomorphic 
bloodstream forms are so named because they have lost the ca-
pacity to generate morphologically stumpy forms through pro-
longed laboratory passage. However, they do retain the capacity 
to differentiate to procyclic forms when stimulated with cis 
aconitate, although this is asynchronous in the population and of 
variable effi ciency. We previously proposed that this asynchrony 
arises from the requirement for individual cells to undergo com-
mitment to differentiation (Matthews and Gull, 1994; Tasker 
et al., 2000). These committed cells remain slender in morphol-
ogy but are functionally equivalent to stumpy forms in terms of 
their ability to differentiate, a condition we have termed stumpy* 
(Tasker et al., 2000; Matthews et al., 2004). We hypothesized that 
the small proportion of monomorphic cells that differentiated in 
response to BZ3 or TbPTP1 RNAi were these stumpy* forms, 
which was supported by the increased differentiation of these 
RNAi lines when incubated with a cAMP analogue reported to 
promote stumpy formation (Fig. S2 C). To further evaluate this, 
we investigated the response to BZ3 of homogenous populations 
of stumpy forms, which are uniformly and irreversibly commit-
ted to differentiation to procyclic forms. Our prediction was that 
these cells would show a highly effi cient differentiation to pro-
cyclic forms in response to BZ3 when compared with cultured 
monomorphic lines.
Initially, we assayed BZ3-induced differentiation in pleo-
morphic slender cells derived from a rodent infection. This 
resulted in an 7% differentiation after 24 h, consistent with 
the response of cultured monomorphic cells (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200605090/DC1). 
Thereafter, trypanosome populations highly enriched for 
stumpy forms were harvested from a mouse infection, and 
these cells were exposed either to 150 μM BZ3, 6 mM cis 
aconitate, or 0.3% vol/vol DMSO (used to solubilize BZ3). In 
all cases, the cells were then maintained in bloodstream-form 
culture conditions (37°C in HMI-9) over a period of 24 h, con-
ditions that are compatible with both effi cient differentiation of 
cis aconitate–stimulated cells (Matthews and Gull, 1997) and 
maintenance of the viability of undifferentiated stumpy forms. 
Samples were harvested at various time points and analyzed 
for the expression of EP procyclin by immunofl uorescence 
and for morphological differentiation by quantitative analysis 
of the kinetoplast–posterior dimension in each cell popula-
tion. Figs. 8 and 9 demonstrate the remarkable result of this 
analysis: stumpy populations differentiated to procyclic forms 
synchronously and effi ciently when exposed to BZ3, with the 
kinetics of this being equivalent to cells exposed to cis aconi-
tate (Matthews and Gull, 1994). Thus, by 6 h in 150 μM BZ3, 
>70% of cells were EP procyclin positive (Fig. 8 A), and by 
24 h the kinetoplast–posterior dimension had increased from 
1 μm (equivalent to that seen in bloodstream forms) to 5 μm 
(equivalent to that in procyclic forms; Matthews et al., 1995; 
Fig. 8 B). In contrast, cells exposed to DMSO alone remained 
as bloodstream stumpy forms and showed no evidence of dif-
ferentiation to procyclic forms (Fig. 9 A). Moreover, by 24 h, 
differentiated cells in the 150 μM BZ3–treated population 
were undergoing cell division as differentiated procyclic forms 
and had induced expression of the procyclic stage–specifi c 
cytoskeletal protein CAP5.5 (Matthews and Gull, 1994; 
Hertz-Fowler et al., 2001; Fig. 9, B and C). We conclude that 
inhibition of TbPTP1 stimulates committed bloodstream-form 
trypanosomes to differentiate to procyclic forms in the absence 
of any previously described trigger for this process.
Discussion
In this study, we report the identifi cation, biochemical charac-
terization, and functional analysis of a novel T. brucei protein 
tyrosine phosphatase, TbPTP1, implicated in life cycle differen-
tiation control in T. brucei. TbPTP1 was originally identifi ed in 
a search for molecular markers of the nondividing bloodstream 
form of T. brucei, by analogy to other molecules associated with 
G0 arrest in eukaryotic cells. Bioinformatics analysis of the 
TbPTP1 sequence and further searches in other kinetoplastid 
genomes revealed the existence of orthologue protein tyrosine 
phosphatases in the other trypanosomatids T. vivax, T. congo-
lense, and T. cruzi. All of them contain the well-defi ned motifs 
conserved in classical PTPs, necessary for catalysis and sub-
strate binding. In addition, distinct motifs are conserved in the 
Figure 8. BZ3 induces synchronous differentiation of stumpy forms. 
(A) EP procyclin expression of stumpy forms after exposure to 6 mM cis 
aconitate, 150 μM BZ3, or 0.3% DMSO. (B) Kinetoplast–posterior dis-
tance (in μm) at each time point for cells under the different treatments. The 
values represent a mean of 100 individual cell measurements under each 
condition at each time point. Error bars indicate SEM.
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trypanosomal subfamily of phosphatases, both in the catalytic 
region and in the N-terminal region, upstream of the catalytic 
domain. We suggest that these Trypanosoma spp.–specifi c mo-
tifs could be important in functional regulation of TbPTP1.
When expressed as a recombinant protein, TbPTP1 
preferentially dephosphorylated phosphotyrosine substrates and 
was inhibited in vitro by sodium orthovanadate, a known 
tyrosine-specifi c phosphatase inhibitor. Moreover, the enzyme was 
regulated by reversible oxidation and mutation of the predicted 
essential catalytic residues C229 and D199 resulted in proteins 
with either severely impaired enzymatic activity (D199A) or total 
inactivity (C229S). Together, these results confi rm the assignment 
of TbPTP1 as a phosphotyrosine-specifi c phosphatase. This con-
trasts with previously reported phosphatases in T. brucei, for which 
our sequence analysis failed to fi nd any of the conserved PTP-
specifi c motifs or any homology to the classical PTPs (Bakalara 
et al., 2000). Thus, TbPTP1 is to our knowledge the fi rst report of 
a cloned gene encoding a bona fi de nonreceptor tyrosine-specifi c 
phosphatase in these organisms.
The biological function of TbPTP1 was investigated by 
two experimental approaches: gene-specifi c RNAi and using a 
cell-permeable PTP1B-specifi c inhibitor in vivo. The fi rst ap-
proach implicated TbPTP1 in life cycle regulation, with sponta-
neous differentiation being observed in a subset of cultured 
bloodstream-form cells. However, this phenotype was unstable, 
and the proportion of differentiated cells was reduced to wild-
type levels with continued culture of the parasites whether cells 
were induced or not. This is not surprising, as transfection pro-
cedures and continued passage at 37°C in bloodstream-specifi c 
culture media would quickly select against populations that 
generate procyclic forms. Moreover, other functions of TbPTP1 
in proliferative bloodstream forms cannot be excluded. There-
fore, we also analyzed the effect of a recently characterized 
cell-permeable allosteric inhibitor of PTP1B, a benzabroma-
rone derivative (Wiesmann et al., 2004). This inhibitor prevents 
the closure of the WPD loop of PTPs, therefore keeping the en-
zyme in a catalytically inactive form. We demonstrated that this 
inhibitor was effective against TbPTP1, but not against the hu-
man low molecular weight PTP (LMWPTP) or a dual-specifi city 
phosphatase. Analysis of the phosphatase complement of the 
complete T. brucei genome identifi ed only two putative proteins 
with an intact WPD loop motif and predicted tyrosine phos-
phatase activity. One of these is TbPTP1, and we have con-
fi rmed its BZ3 sensitivity here. The second enzyme, which we 
term TbPTP2 (Tb11.01.5450), is not likely to contribute to the 
observed differentiation phenotype, as RNAi against this enzyme 
does not elicit differentiation of bloodstream forms (unpublished 
data). Although we cannot exclude other potential uncharacterized 
targets in trypanosomes, the compatible phenotypes resulting 
from genetic and pharmacological inhibition of TbPTP1 impli-
cate this enzyme as being responsible for the differentiation 
phenotype. Moreover, specifi city of the response was further 
supported by the enhanced differentiation observed in BZ3-
treated cells expressing the dominant-negative D199A mutant 
of TbPTP1.
Only a small subset of bloodstream-form cells in asyn-
chronous in vitro cultures were stimulated to differentiate to 
procyclic forms by BZ3. However, the most striking observa-
tion was the effect of this inhibitor on uniform populations of 
stumpy forms. Here, treatment with the PTP1B inhibitor re-
sulted in effi cient differentiation to procyclic forms. We ob-
served that stage-regulated protein expression (EP procyclin; 
CAP5.5), kinetoplast repositioning, and cell cycle progression 
all occurred with equivalent effi ciency and on the same time 
scale as cells treated with cis aconitate, an established trigger 
for trypanosome differentiation. We interpret the differentiation 
of the small proportion of cells in bloodstream cultures as the 
response of the subset of cells in this population, which have 
entered division arrest or committed to other early events in 
stumpy formation, before morphological transformation. We 
previously referred to these cells as stumpy* forms (Tasker 
et al., 2000).
In Fig. 10, we present a model for the role of TbPTP1 in 
the control of bloodstream to procyclic differentiation. In this 
model, bloodstream parasites commit to stumpy formation 
and become competent (stumpy*) to differentiate to procyclic 
forms. However, they are held arrested in this state in the 
bloodstream by the action of TbPTP1. Then, upon uptake by the 
tsetse fl y, this inhibition is removed and the parasites progress 
unhindered to procyclic forms, progressing through a highly 
programmed developmental pathway in which cellular events 
occur on a predetermined pathway and time scale. This model 
has two important implications. First, it supports the concept 
that proliferative slender cells are not competent to differentiate 
to procyclic forms unless they commit to the early events of 
stumpy formation, in particular, cell cycle arrest. Also, it 
Figure 9. The differentiation phenotype of BZ3-treated stumpy forms.
(A) EP procyclin expression and kinetoplast position of stumpy form cells at 
either 0 or 24 h after exposure to DMSO or 150 μM BZ3. (left) Phase-
contrast DAPI-stained images are shown. The kinetoplast position is marked 
with an arrowhead in example cells. Note that repositioning of kinetoplast 
with respect to the cell posterior end occurred only in cells treated with 150 
μM BZ3. (right) The same cells are stained for EP procyclin. (B) Cells were 
treated either with DMSO or 150 μM BZ3 for 24 h and stained with 
CAP5.5. (C) A cell that is undergoing cell division and expresses CAP5.5 
is shown. This indicates cell cycle reentry for the differentiated cells. k, seg-
regated kinetoplasts; n, postmitotic nuclei. Bars, 15 μm.
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suggests that the default pathway for stumpy forms is to differ-
entiate directly to procyclic forms and that this differentiation is 
inhibited in the bloodstream by the action of TbPTP1. In other 
words, differentiation primarily results from release of the 
“brake,” rather than application of the “accelerator.” This sce-
nario is compatible with the role of PTP1 in Dictyostelium slug 
development, where removal of a PTP1 precipitates accelerated 
differentiation via cell aggregation (Howard et al., 1992).
This model does not predict what is the natural signal that 
triggers the inactivation of TbPTP1, although one possibility is 
the different conditions to which the trypanosome is exposed 
upon entering the fl y. For example, pH fl uctuations have been 
observed in the tsetse digestive tract from pH 9.0 to pH 10.2 
(Liniger et al., 2003), at which the activity of TbPTP1 is consid-
erably lower. Potentially combined with other specifi c signals, 
for example, changes in redox conditions upon tsetse uptake, 
this would then inactivate TbPTP1 and license the trypanosome 
for cell cycle reentry and differentiation into a proliferative pro-
cyclic form.
The proposed role of TbPTP1 in preventing inappropriate 
differentiation of stumpy forms in the mammalian bloodstream 
is essential for transmissibility of the parasite. If not strictly 
controlled, the progression to procyclic forms would result in 
rapid death of the stumpy population in the bloodstream be-
cause of either the activation of complement by the alternative 
pathway (killing cells that have lost the variant surface glyco-
protein) or the generation of antibodies to invariant procyclic 
surface antigens. This makes TbPTP1 a key component of the 
regulation of the trypanosome life cycle and hence a potentially 
important pharmacological target for controlling trypanosome 
transmission, for example, in epidemic foci involving intensive 
human–human or human–livestock transmission. If coupled 
with factors to promote stumpy formation, targeting TbPTP1 
may also help limit parasite virulence and promote trypano-
some clearance. There is intense interest in the development of 
PTP1B inhibitors in the pharmaceutical industry because of the 
importance of these enzymes in diabetes and obesity (Ukkola 
and Santaniemi, 2002; Zhang and Lee, 2003), and we are 
currently investigating the opportunity for piggyback strategies 
to target kinetoplastid PTPs. Signifi cantly, the presence of 
trypanosome-specifi c motifs in this enzyme offers the potential 
for developing inhibitors with specifi city for the parasite en-
zyme with respect to their mammalian counterparts.
Materials and methods
Materials
Phosphosubstrates and other chemicals were purchased from Sigma-
Aldrich. The Threonine (KRpTIRR) and Serine (RRApSVA) phosphopeptides 
were obtained from Upstate. The PTP1B inhibitor BZ3 was purchased from 
Calbiochem.
Parasite growth and differentiation
Parasite lines used were T.b. rhodesiense EATRO 2340 GUP2965 (mono-
morphic slender forms) or, for stumpy generation, the isogenic pleomorphic 
line GUP2962 (Matthews and Gull, 1994). For RNAi analyses, T.b. brucei 
Lister 427 single-marker cells were used (a gift from G. Cross, Rockefeller 
University, New York, NY; Wirtz et al., 1999), whereas established procy-
clic forms were T.b. brucei Lister 427.
For BZ3 inhibition assays, cells in HMI-9 medium (Hirumi and 
Hirumi, 1989) at 37°C were exposed to DMSO, PTP1B inhibitor BZ3, or 
6 mM cis aconitate. Samples were assayed by immunoﬂ uorescence at room 
temperature using antibody to EP procyclin (diluted 1:500 in PBS; Cedar 
Lane Laboratories), antibody to GPEET (diluted 1:200; a gift from I. Roditi, 
University of Bern, Bern, Switzerland), or the procyclic form cytoskeletal 
protein CAP5.5 (undiluted hybridoma supernatant; a gift from K. Gull, Uni-
versity of Oxford, Oxford, England; Hertz-Fowler et al., 2001). Secondary 
antibodies used were goat anti–mouse (EP procyclin; CAP5.5) or –rabbit 
(GPEET procyclin) conjugated to either FITC (1:50; Sigma-Aldrich) or 
Alexa 488 (1:200; Invitrogen). Slides were stained with 1 μg/ml DAPI and 
mounted in MOWIOL (Harlow Chemical Co.). Morphometric measure-
ments of kinetoplast repositioning used Scion Image 1.62. Images were 
captured using a Cohu charged-coupled device camera attached to an 
 Axioscope 2 (Carl Zeiss MicroImaging, Inc.) using either Plan Neoﬂ uar 63× 
(1.25 NA) or Plan Neoﬂ uar 100× (1.30 NA) phase-contrast objectives. 
Images were processed using Photoshop CS (Adobe).
DNA cloning
A 595-bp fragment related to PTPROt (Aguiar et al., 1999) formed part of 
the sheared T. brucei strain TREU 927/4 genomic DNA clone 18E19 
(available from GenBank/EMBL/DDBJ under accession no. AQ649023). 
Oligonucleotides were designed to the 5′ (TbPTP A; 5′-C A T C A A C C T C G T A-
C G A C G -3′) and 3′ (TbPTP B; 5′-C A A G C C A T A C A A T A A T T G -3′) ends of the 
gene fragment, and were these used in independent ampliﬁ cations with 
primers speciﬁ c for the spliced leader sequence or polyA tail to amplify the 
gene in two overlapping halves from cDNA. The sequence of the full gene 
was veriﬁ ed after completion of the trypanosome genome sequence.
Northern and Western blotting
RNA preparation and Northern blotting was performed as described by 
Tasker et al. (2000) using a digoxygenin-labeled TbPTP1-speciﬁ c ribo-
probe (Roche). Stumpy cell fractionation used the Qproteome kit (QIA-
GEN) with each fraction being probed with antibodies to α-tubulin 
(cytoskeletal fraction; a gift from K. Gull), cytosolic PGK (cytosol; a gift from 
P. Michels, Université Catholique de Louvain, Brussels, Belgium), and BiP 
(membrane and organelles; a gift from J. Bangs, University of Wisconsin, 
Madison, WI) as controls. For detection of TbPTP1, an anti-peptide 
(NH2-A M K Q K R F G M V Q R L E Q -COOH) antibody was raised in rabbits and 
afﬁ nity puriﬁ ed against the immunogen (Eurogentec). Preimmune serum 
detected no trypanosome protein. Western blotting was performed accord-
ing to Tasker et al. (2000).
Figure 10. A model for the control of bloodstream to procyclic form dif-
ferentiation in trypanosomes. In the bloodstream, slender forms transform 
to stumpy forms and then stay arrested, with further differentiation being 
inhibited by the action of TbPTP1. Once in the tsetse midgut, inhibition of 
stumpy form differentiation is released and procyclic forms are generated. 
Inactivation of TbPTP1 function by RNAi or treatment with the BZ3 inhibitor 
mimics the release of differentiation blockage observed in the natural life 
cycle and results in direct differentiation of stumpy forms to procyclic forms, 
despite the absence of other differentiation stimuli.
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RNAi and ectopic expression for TbPTP1 and mutants
TbPTP1 transcript ablation in bloodstream forms was achieved by cloning 
the TbPTP1 coding sequence into pZJM (Wang et al., 2000), which was 
then linearized by NotI digestion and transfected as previously described. 
Transformants were selected with 2.5 μg/ml phleomycin. Ectopic overex-
pression of TbPTP1 and D199A mutants used the trypanosome expression 
vector pHD451.
Phosphatase assays using phosphosubstrates
Dephosphorylation of phosphosubstrates was detected by measuring the 
release of inorganic phosphate with the malachite green detection system 
according to the manufacturer’s protocol (Protein tyrosine phosphatase as-
say kit; Sigma-Aldrich). Reaction mixtures (50 μl) contained 5–10 μg of 
puriﬁ ed TbPTP1 with concentrations from 0.01 to 0.2 mM of phosphopep-
tides in 50 mM Hepes and 150 mM NaCl, pH 7.0. Reactions were incu-
bated at 37°C for 15–30 min and quenched by adding of 50 μl of 
malachite green reagent. After 15 min of further incubation at room tem-
perature, the absorbance of the samples were measured at 620 nm in a 
microplate reader (Opsys MR; Dynex Technologies), with released inor-
ganic phosphate being determined using a phosphate standard curve. The 
speciﬁ c activity is deﬁ ned as pmoles of inorganic phosphate released in a 
minute per milligram of protein. Kinetic constants Km and Vmax were 
calculated using the Lineweaver-Burke plot of the reciprocal initial velocity 
versus the reciprocal concentration of substrates. See the supplemental text 
(available at http://www.jcb.org/cgi/content/full/jcb.200605090/DC1)
for information about protein expression constructs and recombinant protein 
puriﬁ cation.
Phosphatase assays using pNPP
Enzyme activity was measured by monitoring TbPTP1 (5–20 μg) catalyzed 
hydrolysis of pNPP to p-nitrophenol (Zhang and Van Etten, 1990). A ﬁ nal 
concentration of 20 mM pNPP was present in the assay. The pNPP assay 
buffer was 50 mM Tris, 50 mM bisTris, and 100 mM Na acetate, pH 
5–7.5. Each reaction (400 μl) was performed in triplicate, being incu-
bated at 37°C for 15 min and quenched by adding 500 μl of 1 M NaOH. 
The concentration of released p-nitrophenol, determined at 405 nm, was 
converted to millimolar units using a millimolar extinction coefﬁ cient of 
18.0 mM−1 cm−1.
Reversible inactivation of TbPTP1 by H2O2
The assays (120 μl) contained 60 μg of TbPTP1 and 0–0.25 mM H2O2 in 
50 mM Hepes, pH 7.0, and 150 mM NaCl. Reactions, initiated by addi-
tion of H2O2, were incubated at room temperature. After 15 min, 10 mM 
DTT was added. 20-μl samples removed at 0, 5, 10, 15, 20, 30, and 40 
min were assayed for residual activity using pNPP as substrate.
Online supplemental material
Table S1 shows kinetic constants for the hydrolysis of phosphosubstrates 
by TbPTP1. Fig. S1 shows immunoﬂ uorescence localization of ectopically 
expressed TbPTP1. Fig. S2 shows growth kinetics, RNA, and protein ex-
pression of the TbPTP1 RNAi line and the response of the TbPTP RNAi 
line to pCPTcAMP. Fig. S3 shows BZ3 response of pleomorphic slender 
cells. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200605090/DC1.
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